PMID: 15218398Jun 26, 2004Paper

Pharmacologic elevation of high-density lipoproteins: recent insights on mechanism of action and atherosclerosis protection

Current Opinion in Cardiology
C Daniel Meyers, M L Kashyap

Abstract

Despite the best efforts in reduction of low-density lipoprotein cholesterol, most cardiovascular events are not being prevented. Because high-density lipoprotein (HDL) promotes reverse cholesterol transport and other antiatherogenic effects, interventions aimed at raising HDL cholesterol or mimicking its beneficial effects may greatly improve treatment and prevention of cardiovascular disease. This article reviews the antiatherogenic effects of HDL, recent insights into the mechanisms of action of currently available, and emerging HDL-based therapies. New insights into the basic science of HDL function and metabolism (such as the discovery of beta-chain ATP synthase as a hepatic catabolic HDL receptor) are further characterizing the importance of HDL in atheroprotection and identifying novel targets of drug development. Nicotinic acid, fibrates, statins, and thiazolidinediones not only increase HDL cholesterol but also alter HDL subpopulation size and composition. Furthermore, these drugs promote direct antiatherogenic effects of HDL (antioxidation, anti-inflammation, antithrombotic effects, endothelial stabilization). Emerging HDL-raising therapies (such as cholesteryl ester transfer protein inhibitors and 1,2-dimyristoyl-sn-...Continue Reading

References

Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·S M HammadW S Argraves
Dec 21, 2000·Current Atherosclerosis Reports·V S Kamanna, M L Kashyap
Jun 8, 2001·The Journal of Clinical Investigation·G MartinB Staels
May 15, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·O BarbierB Staels
Jun 25, 2002·Annals of the New York Academy of Sciences·Virginie BocherBart Staels
Jul 18, 2002·Atherosclerosis·Anne TailleuxVéronique Clavey
Jan 28, 2003·Progress in Lipid Research·Ken KarasawaMorio Setaka
Feb 4, 2003·Nature Medicine·Sorin TunaruStefan Offermanns
Feb 8, 2003·Atherosclerosis. Supplements·Michael I MacknessPaul N Durrington
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Philip J BarterAlan R Tall
Mar 4, 2003·Journal of Lipid Research·Vasilis TsimihodimosAlexandros D Tselepis
Mar 5, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Minghui QinBehrooz G Sharifi
Mar 15, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Bela F AsztalosErnst J Schaefer
Mar 19, 2003·Current Opinion in Lipidology·Giulia Chiesa, Cesare R Sirtori
Jun 14, 2003·The American Journal of Cardiology·John M MorganKalen Walker
Jul 15, 2003·Current Opinion in Cardiology·Juan F Viles-GonzalezJuan J Badimon
Jul 23, 2003·The Journal of Nutritional Biochemistry·Shobha H GanjiMoti L Kashyap
Aug 9, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Jeroen P H van WijkTon J Rabelink
Sep 6, 2003·The American Journal of Cardiology·Daniel J Rader
Sep 13, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Laura CalabresiGuido Franceschini
Sep 23, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Sara DeakinRichard W James
Oct 11, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Nicola FransciniGabriele Schoedon
Oct 16, 2003·Current Cardiology Reports·Shaista Malik, Moti L Kashyap
Nov 6, 2003·JAMA : the Journal of the American Medical Association·Steven E NissenRichard Kerensky
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Moti L KashyapVaijinath S Kamanna

❮ Previous
Next ❯

Citations

Jun 1, 2005·Biochimica Et Biophysica Acta·Gerd Schmitz, Thomas Langmann
May 3, 2012·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Michele L Mietus-SnyderBruce N Ames
Aug 21, 2007·Annual Review of Pharmacology and Toxicology·Andreas GilleStefan Offermanns
Dec 3, 2005·The Journal of Clinical Investigation·Zoltán BenyóStefan Offermanns
Dec 12, 2012·European Urology·Elizabeth M MaskoStephen J Freedland
Mar 1, 2007·Journal of Clinical Lipidology·James M McKenney
Feb 7, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G ZoppiniM Muggeo
Jun 2, 2010·Journal of Atherosclerosis and Thrombosis·Shizuya YamashitaMakoto Nishida
Jan 13, 2015·BMC Medicine·Pao-Hwa LinStephen J Freedland
Mar 27, 2010·Journal of the American College of Cardiology·Pradeep NatarajanChristopher P Cannon
Jun 6, 2006·Journal of the American College of Cardiology·Markus ExnerMartin Schillinger
Oct 7, 2004·Journal of Lipid Research·Lawrence W CastellaniAldons J Lusis
Sep 18, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Shucun QinMoti L Kashyap
Jun 16, 2005·Current Opinion in Cardiology·C Daniel Meyers, Moti L Kashyap
May 26, 2010·Yonsei Medical Journal·Eun Sook Hwang
Oct 13, 2006·The Journal of Pharmacy and Pharmacology·Ricardo Pérez-PasténGermán Chamorro
Apr 19, 2012·Current Opinion in Lipidology·Maryse Guerin
Mar 4, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ha Young LeeYoe-Sik Bae
Feb 7, 2012·Journal of Cardiovascular Pharmacology and Therapeutics·Shucun QinMoti L Kashyap
Aug 29, 2006·Arquivos brasileiros de endocrinologia e metabologia·Rodrigo O MoreiraRosane Kupfer

❮ Previous
Next ❯

Related Concepts

Related Feeds

ATP Synthases

ATP synthases are enzymes located in the inner mitochondrial membrane that catalyze the synthesis of ATP during cellular respiration. Discover the latest research on ATP synthases here.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.